Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Timeline
  • Published:

The Common Technical Document: the changing face of the New Drug Application

Abstract

Drug approval is the goal of the long process of drug development. Once preclinical and clinical trial data have been collected, a New Drug Application must be submitted to the regulatory authority for approval. Although the requirements for this submission have similarities around the world, until now, the applications have been different. Regulatory authorities working under the umbrella of the International Conference on Harmonisation are hoping that the development of the Common Technical Document will soon harmonize the application procedure, and make this process simpler for applicants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The approval process.
Figure 2: The CTD triangle.

Author information

Authors and Affiliations

Authors

Related links

Related links

FURTHER INFORMATION

Center for Drug Evaluation and Research

Center for Drug Evaluation and Research Handbook

Center for Drug Evaluation and Research Learn

European Commission of the European Union

European Federation of Pharmaceutical Industries and Associations

Food and Drug Administration

International Conference on Harmonisation

International Federation of Pharmaceutical Manufacturers Association

Ministry of Health, Labour and Welfare

Pharmaceutical Research and Manufacturers of America

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molzon, J. The Common Technical Document: the changing face of the New Drug Application. Nat Rev Drug Discov 2, 71–74 (2003). https://doi.org/10.1038/nrd990

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd990

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing